Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Jazz Pharma's JZP-110 for the treatment of Obstructive Sleep Apnea (OSA) and TONES 3 and TONES 4 study results

Ticker(s): JAZZ, AVDL

Who's the expert?

Name: Dr Charlene Gamaldo - MD

Institution: Johns Hopkins

  • Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
  • Actively treats over 1,500 patients with OSA and 30 with narcolepsy.
  • Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.

Interview Questions
Q1.

Please describe your current practice. How many patients do you treat with OSA? 

Added By: c_admin
Q2.

How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?

Added By: c_admin
Q3.

On a scale from 1-10, where would you put your level of excitement for JZP-110?

Added By: c_admin
Q4.

Is there anything else on the horizon for OSA that you think is promising?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.